Core Viewpoint - UroGen Pharma Ltd. is facing a class action lawsuit due to allegations of misleading statements regarding the effectiveness of its lead pipeline product, UGN-102, during the class period from July 27, 2023, to May 15, 2025 [3][4]. Group 1: Allegations - The complaint claims that the ENVISION clinical study was inadequately designed, lacking a concurrent control arm, which undermines the evidence of UGN-102's effectiveness [3]. - It is alleged that UroGen Pharma did not heed FDA warnings about the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [3]. - The lawsuit asserts that the company's positive statements regarding its business and prospects were materially misleading and lacked a reasonable basis due to the aforementioned issues [3]. Group 2: Class Action Details - Shareholders who purchased URGN shares during the specified class period are encouraged to register for the class action, with a deadline set for July 28, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - There is no cost or obligation for shareholders to participate in the class action [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A lawsuit has been filed against UroGen Pharma Ltd. and certain senior executives for potential violations of federal securities laws, specifically related to the company's claims about its lead product UGN-102 and its clinical trial results [1][2]. Company Overview - UroGen Pharma Ltd. focuses on developing treatments for specialty cancers, with its lead product being UGN-102, an intravesical solution aimed at treating low-grade intermediate risk non-muscle invasive bladder cancer [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Cockrell v. UroGen Pharma Ltd., et al., No. 3:25-cv-06088, and investors have until July 28, 2025, to seek lead plaintiff status [2]. Allegations - The complaint alleges that UroGen misrepresented the success of the ENVISION trial, claiming it met its primary endpoint and that the FDA had agreed the trial would support a New Drug Application (NDA) submission [3]. - In reality, the FDA had raised significant concerns about the trial's design, particularly its lack of a concurrent control arm [4]. Stock Performance - Following the FDA's briefing document on May 16, 2025, which questioned the effectiveness of UGN-102, UroGen's stock price fell by $2.54 per share, a decline of nearly 26%, from $9.85 to $7.31 [5]. - On May 21, 2025, after the Oncologic Drugs Advisory Committee voted against the approval of the UGN-102 NDA, the stock dropped by $3.37 per share, nearly 45%, from $7.54 to $4.17 [6]. Legal Options for Investors - Investors who suffered losses are encouraged to submit their information to the law firm representing the class action, with representation on a contingency fee basis [7].

Core Viewpoint - UroGen Pharma Ltd. is facing allegations related to misleading statements and study design issues concerning its lead pipeline product, UGN-102, during the class period from July 27, 2023, to May 15, 2025 [2]. Group 1: Allegations and Legal Context - The complaint alleges that the ENVISION clinical study was not adequately designed to demonstrate the effectiveness of UGN-102 due to the absence of a concurrent control arm [2]. - It is claimed that UroGen Pharma failed to address FDA warnings regarding the study design, leading to substantial risks regarding the approval of the New Drug Application (NDA) for UGN-102 [2]. - The allegations suggest that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased URGN shares during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for July 28, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - UroGen Pharma Ltd. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims centered around misleading statements regarding the effectiveness of its lead product, UGN-102, and its clinical study design [1][3]. Company Overview - UroGen Pharma Ltd. specializes in developing and commercializing solutions for specialty cancers, with its primary product being UGN-102, an intravesical solution aimed at treating low-grade intermediate risk non-muscle invasive bladder cancer [2]. Allegations of the Lawsuit - The lawsuit claims that UroGen made false or misleading statements and failed to disclose critical information regarding the ENVISION clinical study for UGN-102, including: - The study was not designed to provide substantial evidence of effectiveness due to the absence of a concurrent control arm [3]. - UroGen's challenges in demonstrating that the duration of response was attributable to UGN-102 [3]. - Ignoring FDA warnings about the study design for the new drug application (NDA) [3]. - The substantial risk that the NDA for UGN-102 would not receive approval [3]. Impact of FDA Findings - On May 16, 2025, the FDA released a briefing document indicating concerns about the ENVISION study's design, stating that the primary endpoints were difficult to interpret due to the lack of a concurrent control arm. This led to a nearly 26% drop in UroGen's stock price [4]. - Following the FDA's Oncologic Drugs Advisory Committee vote against the approval of UGN-102 on May 21, 2025, citing unfavorable benefit-risk assessment, UroGen's stock price fell nearly 45% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased UroGen securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7].

Core Viewpoint - A class action lawsuit has been filed against UroGen Pharma Ltd. for alleged violations of federal securities laws during the Class Period from July 27, 2023, to May 15, 2025 [1] Group 1: Allegations Against UroGen - The lawsuit claims that UroGen and its officers made false or misleading statements regarding the ENVISION clinical study, which was not designed to provide substantial evidence of effectiveness for UGN-102 due to the absence of a concurrent control arm [2] - It is alleged that UroGen failed to heed FDA warnings about the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [2] - The misleading statements made by UroGen regarding its business and prospects resulted in significant investor losses when the truth was revealed [2][3] Group 2: Investor Impact - Investors who suffered losses exceeding $50,000 in UroGen's securities are encouraged to participate in the lawsuit, with a deadline to act before July 28, 2025 [3] - The decline in UroGen's stock price following the revelation of the truth has caused significant financial injury to investors [3] Group 3: About the Law Firm - Lowey Dannenberg P.C. is a law firm specializing in representing institutional and individual investors who have suffered financial losses due to corporate fraud and violations of federal securities laws [4] - The firm has a strong track record in prosecuting multi-million-dollar lawsuits and has recovered billions for its clients [4]

Core Viewpoint - A class action securities lawsuit has been filed against UroGen Pharma Ltd. for alleged securities fraud affecting investors between July 27, 2023, and May 15, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that the ENVISION clinical study was inadequately designed, lacking a concurrent control arm, which undermined the evidence of effectiveness for UGN-102 [2] - It is alleged that UroGen Pharma did not heed FDA warnings regarding the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [2] - Defendants' positive statements about the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis due to the aforementioned issues [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until July 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - UroGen Pharma (NASDAQ: URGN) is rated as a "hold" ahead of its upcoming Prescription Drug User Fee Act (PDUFA) review for UGN-102 (mitomycin) [2] Company Analysis - The FDA has set a date to review the regulatory application of UGN-102, which is an intravesical treatment [2] - The article is part of a broader service that provides in-depth analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2]

Core Viewpoint - A lawsuit has been filed against UroGen Pharma Ltd. and certain senior executives for potential violations of federal securities laws, specifically related to the company's claims about its lead product UGN-102 and its clinical trial results [1][2]. Company Overview - UroGen Pharma Ltd. focuses on developing treatments for specialty cancers, with its primary product being UGN-102, an intravesical solution aimed at treating low-grade intermediate risk non-muscle invasive bladder cancer [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the District of New Jersey, with investors having until July 28, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased UroGen securities [2]. Clinical Trial Issues - UroGen claimed that its ENVISION trial met its primary endpoint and that it had reached an agreement with the FDA to support a New Drug Application (NDA) submission [3]. - However, the FDA had previously raised significant concerns about the ENVISION trial, noting the absence of a concurrent control arm [4]. Stock Performance - Following the FDA's briefing document on May 16, 2025, which questioned the effectiveness of UGN-102 due to the trial's design, UroGen's stock price fell by $2.54, or nearly 26%, from $9.85 to $7.31 per share [5]. - On May 21, 2025, after the Oncologic Drugs Advisory Committee voted against the approval of UGN-102's NDA, the stock price dropped by $3.37, or nearly 45%, from $7.54 to $4.17 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against UroGen Pharma Ltd. due to alleged securities fraud affecting investors between July 27, 2023, and May 15, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that UroGen Pharma Ltd. made false statements regarding the ENVISION clinical study, claiming it was not designed to provide substantial evidence of effectiveness for UGN-102 due to the absence of a concurrent control arm [2]. - It is claimed that UroGen Pharma Ltd. would struggle to demonstrate that the duration of response endpoint was attributable to UGN-102, and that the company ignored FDA warnings about the study design [2]. - The lawsuit suggests that there was a significant risk that the New Drug Application (NDA) for UGN-102 would not be approved, leading to misleading positive statements about the company's business and prospects [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/urogen-pharma-ltd-loss-submission-form/?id=151949&from=3 CLASS PERIOD: July 27, ...